Skip to content
Axcess News – Lifestyle
Author:
AbbVie
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 30, 2026
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
June 29, 2026
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
June 29, 2026
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
June 26, 2026
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
June 26, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective’s Entrepreneur Class of 2026
June 24, 2026
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
June 23, 2026
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
June 23, 2026
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
June 23, 2026
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 22, 2026
1
2
Next Page
→